Entzündliche Hauterkrankungen

Nr./ EudraCT

Sponsor / Studie / Kurztitel

Phase

Indikation

Prüfgruppe

Studienstatus

1. 2022-003477-36

SHIVAP- Psorias, Safety and immunogenicity of SHIngrix VAccination in patients suffering

from Psoriasis or Psoriatic arthritis (SHIVAP)

4

Psoriasis

Dr. Manuel Göbel, Dr. Lisa Krönig, Dr. Julia Hinterseher

Aktiv/ Rekrutierung aktiv

2/2023-503692-24-00

Lavender, Anifrolumab, A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy

3

Lupus Erythematosus

Prof. Hertl,                    Dr. Hinterseher,

A. Santos, Dr. Göbel,

L. Henk

Aktiv/ Rekrutierung aktiv

3/ 2024-511879-16-00

Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis

3

Prurigo Nodularis

Prof. Hertl,

Dr. Hinterseher,

A. Santos,

L. Henk

Aktiv/ Rekrutierung aktiv

4/ 2021- 000271- 36

Philipps Uni. Marburg/ 2021-000271-36/ Guselkumab in patients with oral Lichen planus: An open label, parallel, randomized, multicenter, phase II trial

2

Oraler Lichen planus

Prof. Hertl; J. Hinterseher

Aktiv/ Rekrutierung abgeschlossen